As reported by Bloomberg, Mepact, Takeda Pharmaceutical Co.’s bone cancer drug has won backing from the UK National Institute of Health and Clinical Excellence (NICE). The drug has been approved for the treatment of bone cancer in children.
NICE has advised that Mepact is used in combination with chemotherapy after surgery for young patients with bone cancer which hasn’t yet spread. NICE stated that more patients were successfully cured of osteosarcoma (the most common form of bone cancer) when taking the drug alongside surgery and chemotherapy.
Looking for a job in the Pharmaceutical Industry? Click here to search our current pharmaceutical jobs now.